
CLAIMS

Claim 1. A compound of formula I:



or a salt, hydrate or stereoisomer thereof, wherein:

Q is selected from cyclopropane-1,2-diyl, (CH2)2;

X, Y, Z and W are each independently selected from CR and N; R=H, halogen, CH3, optionally fluorinated, optionally deuterated;

L is selected from: -SCH2C(O)-, - CH2NHSO2-, -O(CH2)n- [n = 2], -OCH2CHR- [R = OH, OMe, OCF3, OCHF2, OCH2F], -(CH2)nC(O)- [n =2], -CHRCH2C(O)- [R = OH],, -CHORCH2n- [n = 2; R = H], -(CH2)nCHOR- [n = 2; R = H, Me, CF3, CHF2, CH2F], -CH=CHC(O)-, CH=CHCHR- [R = OH, OMe, OCF3, OCHF2, OCH2F], -C≡CC(O)-, -C≡CCHR [R = OH, OMe, OCF3, OCHF2, OCH2F], -(cyclopropane-1,2-diyl)C(O)-, -(cyclopropane-1,2-diyl)CHR- [R = OH, OMe, OCF3, OCHF2, OCH2F],; and

Ar is selected from 2-, or 3- or, 4-mono- or, di- or trisubstituted phenyls, with preferred substituents selected from halogen, Me, OMe, cycloPr, CN, each optionally fluorinated and optionally deuterated; and optionally substituted phenyls and heteroaryls; mono- and fused bicyclic heteroaryl, heteroaryl, fused aryls (naphthyls), each optionally deuterated, with optional substituents selected from halogen, Me, OMe, cPr, CN, each optionally fluorinated and optionally deuterated.

Claim 2. The compound of claim 1, wherein:
Q is cyclopropane-1,2-diyl.

Claim 3. The compound of claim 1, wherein:
X is N and Y, Z and W are each CH; or X, Y, Z and W are each CH.

Claim 4. The compound of claim 1, wherein:
L is selected from: -SCH2C(O)-, CH2NHSO2-, -(CH2)2C(O)-, -O(CH2)2-, -OCH2CHOH-, -CH(OH)(CH2)2-, and -(cyclopropane-1,2-diyl)C(O)-, .


Claim 5. The compound of claim 1, wherein:

Ar is 2-, or 3- or, 4-mono- or, di- or trisubstituted phenyls, with substituents selected from halogen, Me, OMe, cycloPr, and CN, preferably halogen, Me and OMe, each optionally fluorinated and optionally deuterated.


Claim 6. The compound of claim 1, wherein:
Q is cyclopropane-1,2-diyl;
X is N and Y, Z and W are each CH; or X, Y, Z and W are each CH; and
Ar is 2-, or 3- or, 4-mono- or, di- or trisubstituted phenyls, with substituents selected from halogen, Me or OMe, cycloPr, and CN, preferably halogen, Me and OMe, each optionally fluorinated and optionally deuterated.

Claim 7. The compound of claim 1, wherein:
Q is cyclopropane-1,2-diyl;
X is N and Y, Z and W are each CH; or X, Y, Z and W are each CH;
L is selected from: -SCH2C(O)-, CH2NHSO2-, -(CH2)2C(O)-, -O(CH2)2-, -OCH2CHOH-, -CH(OH)(CH2)2-, and -(cyclopropane-1,2-diyl)C(O)-; and
Ar is 2-, or 3- or, 4-mono- or, di- or trisubstituted phenyls, with substituents selected from halogen, Me or OMe, cycloPr, and CN, preferably halogen, Me and OMe, each optionally fluorinated and optionally deuterated.


Claim 8. A compound of claim 1,
having a structure selected from the following:



, wherein LINKER-Aryl is



























wherein Ph is phenyl and PMP is p-methoxy-phenyl; or




, wherein R is

3-Cl,4-OMe;
3-Me,4-Cl;
3-Cl,4-F;
3-CF_3,4-Cl;
3-Cl, 4-Cl; or
3-Cl, 5-Cl; or

any one of



Claim 9. A compound of any one of claims 1 to 8, wherein the compound inhibits lanosterol synthase (LSS).

Claim 10. A pharmaceutical composition comprising a compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

Claim 11. A small molecule lanosterol synthase inhibitor of any one of claims 1 to 8 for use in medicine, the use comprising

(i) inhibiting lanosterol synthase;

(ii) upregulating 24,25-epoxycholesterol (EPC); or

(iii) treating a neurological disease or condition.

Claim 12. The small molecule lanosterol synthase inhibitor for use according to claim 11, wherein the neurological disease or condition is glioblastoma (GBM) or a neurodegenerative disease, such as amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease.

Claim 13. The small molecule lanosterol synthase inhibitor for use according to claim 11, further comprising the antecedent step of detecting or diagnosing the disease or condition and/or the subsequent step of detecting a resultant improvement or delay of progression of the disease or condition.

Claim 14. An *In vitro* method of screening for candidate therapeutics for treating a neurological disease or condition, the method comprising identifying inhibitors of lanosterol synthase (p75).